FDA Closes the 503B Bulks Door on Semaglutide, Tirzepatide, and Liraglutide: How the April 30 Proposal Kills the Compounded GLP-1 Supply Chain and Draws a Hard Line Between Clinical Need and Economic Need

Thoughts on Healthcare Markets & Technology Podcast

FDA Closes the 503B Bulks Door on Semaglutide, Tirzepatide, and Liraglutide: How the April 30 Proposal Kills the Compounded GLP-1 Supply Chain and Draws a Hard Line Between Clinical Need and Economic Need — Part II

0:00

-12:09

Paid episode

The full episode is only available to paid subscribers of Thoughts on Healthcare Markets & Technology

FDA Closes the 503B Bulks Door on Semaglutide, Tirzepatide, and Liraglutide: How the April 30 Proposal Kills the Compounded GLP-1 Supply Chain and Draws a Hard Line Between Clinical Need and Economic Need — Part II

On April 30, 2026, FDA proposed excluding the three major GLP-1 drugs from the 503B bulks list — here is exactly what that does and who it kills.

May 04, 2026

∙ Paid

The FDA's April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List is the regulatory end of compounded GLP-1s from outsourcing facilities. The stated rationale is that no clinical need exists for 503B compounding when the branded products are commercially available. This episode breaks down what the proposal …

Continue reading this post for free, courtesy of Thoughts on Healthcare.

Or purchase a paid subscription.